Skip to main content

Month: July 2020

First Commercial Product Using Antares Pharma’s Multi-Dose Pen Platform Launches in Europe

EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the Company’s multi-dose pen platform launched in Europe. Antares development partner Teva, launched Teriparatide Injection (“teriparatide”), the generic version of Eli Lilly’s brand product Forsteo®  featuring the Antares multi-dose pen platform in Austria, Croatia, Hungary, The Netherlands, Portugal, Sweden, Switzerland and The United Kingdom and is expected to launch in other European countries later this year.Teriparatide injection is a drug-device combination product indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men, and in postmenopausal women and in men at increased risk...

Continue reading

NaturalShrimp’s Amoebic Gill Disease Technology Completes Successful Phase-I Testing

Dallas, TX, July 21, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NaturalShrimp, Inc. (OTCMKTS: SHMP), announced today that CSIRO Agriculture and Food’s Aquaculture Research Team in Tasmania, Australia (one of the world’s leading aquaculture institutes) has successfully completed Phase-I in vitro testing of a new technology that has proven effective at killing Neoparamoeba perurans, the parasite which causes Amoebic Gill Disease (AGD) of Atlantic salmon. With Phase-I efficacy completed, CSIRO has already received ethics approval for starting Phase-II, which will focus on fish welfare during the experimental treatment.NaturalShrimp is funding the CSIRO research on the AGD technology through its market development partnership with Hydrenesis, Inc. (Hydrenesis), the exclusive, worldwide commercialization agent for the AGD technology...

Continue reading

REPEAT – Ready, Set, Smoke! Taat Herb Co. Publishes Footage from Beyond Tobacco™ Production Run

Through production vendor Hempacco, Taat has completed a test production run of Beyond Tobacco™ cigarettes which has confirmed their suitability for full-scale production, matching initial capacity estimations of one million sticks per day. Taat has published footage of the test production run, which is available on its website and its social media channels. The output from this production run is to be used in a series of intensive focus groups in which current tobacco smokers will provide feedback about the similarity of Beyond Tobacco™ to legacy tobacco products. Additionally, the Company will be able to issue samples of Beyond Tobacco™ cigarettes to prospective distributors, which could encourage such potential distributors to carry Beyond Tobacco™ and promote the product to their respective distribution networks.LAS VEGAS and VANCOUVER,...

Continue reading

Global WholeHealth Partners with 1 Drop Inc. to Sell FDA Approved COVID-19 rt-PCR in the US Market, as Mentioned in the July 16th 8K Filing

San Clemente, CA, July 21, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Global WholeHealth Partners Corp. (OTC PINK:GWHP) announced today that it’s authorized to sell FDA Approved COVID-19 rt-PCR from 1 Drop Inc.Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp, said, “The Company’s goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability #2260-11-2019 for tests like Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.”Global WholeHealth Partners...

Continue reading

Rapid Dose Therapeutics and McMaster University Initiate QuickStrip™ COVID-19 Vaccine Research With Immediate Impact

BURLINGTON, Ontario, July 21, 2020 (GLOBE NEWSWIRE) — Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian Life Sciences company focused on innovative drug and active ingredient delivery solutions, is pleased to announce it has begun COVID-19 vaccine research in conjunction with McMaster University and the team lead by Drs. Alex Adronov, James Mahony, and Mark Larché. The federally-funded project tests the use of QuickStrip™ for administering vaccines orally as a convenient and safe alternative to injection with needles, the currently accepted delivery format for most vaccines.Dr. Adronov is a recognized Canadian expert in synthetic polymer chemistry and the development of novel polymer architectures, Dr. Mahony has extensive experience in virology and vaccine development, and Dr. Larché is an immunologist...

Continue reading

CTG Reports 2020 Second Quarter Results

Achieved GAAP EPS of $0.12; non-GAAP EPS of $0.10, Performing Well in Challenging COVID-19 Pandemic EnvironmentOperating Margin Increased 30 Basis Points to 2.1%, or 16%, Year-over-YearNon-GAAP Operating Margin Increased 83 Basis Points to 3.2%, or 35%, Year-over-YearSolutions Expanded to 38% of Revenue as Strategic Transformation ContinuesBUFFALO, N.Y., July 21, 2020 (GLOBE NEWSWIRE) — CTG (NASDAQ: CTG), a leading provider of information technology (IT) solutions and services in North America and Western Europe, today announced its financial results for the second quarter ended June 26, 2020.Second Quarter Financial SummaryTotal revenue was $89.1 million, compared with $86.9 million in the previous quarter and $100.4 million in the second quarter of 2019Revenue from Solutions increased to 38.0% of total revenue, compared with 35.5%...

Continue reading

Comstock Mining Announces Positive Net Income for Second Quarter; Readies Transport of Mercury Remediation Systems to the Comstock Lode and the Philippines

VIRGINIA CITY, Nev., July 21, 2020 (GLOBE NEWSWIRE) — Comstock Mining Inc. (the “Company”) (NYSE American: LODE) announced selected strategic and financial updates (unaudited) for the second quarter and year to date:Selected Strategic Highlights Investments in Mercury Clean Up LLC (“MCU”) increased to $1.75 million in cash and stock to date with the Comstock mercury remediation system completed (pictures below) and shipping this week;Committed to investing in MCU Philippines Inc. after MCU agreed to a definitive joint venture agreement with Clean Ore Solutions OPC, to partner in a landmark mercury remediation project in the Philippines;Committed up to $3 million in debt and equity investments, for 62.5% of the newly created MCU Philippines Inc., with the new mercury remediation system ready for shipment (pictures below); andConsummated...

Continue reading

Stantec awarded bridge inspection contracts across three US states

EDMONTON, Alberta and NEW YORK and DENVER, July 21, 2020 (GLOBE NEWSWIRE) — TSX, NYSE:STN – Stantec has been selected to provide bridge inspection services for three US State Departments of Transportation (DOT): Nevada (NDOT), Colorado (CDOT), and North Dakota (NDDOT). The work carried out by Stantec’s bridge inspection teams will use the latest technology and engineering methodology to ensure the bridges are safe for the traveling public and that they can continue to serve their communities.The global demand for routine bridge inspections is set to quadruple from current levels to a market valuation of $6.3 billion by the end of 2029, according to research firm Fact.MR. The increased demand will be driven by aging infrastructure, damaging environmental conditions, and the wear and tear from increased traffic.“Bridges connect...

Continue reading

Teleflex Announces Positive Data Emphasizing the Effectiveness of the UroLift® System Treatment for Enlarged Prostate Across Broad Patient Populations

Data Presented at European Association of Urology Highlights Safety and Versatility of the Minimally Invasive UroLift System in a Real-World SettingWAYNE, Pa., July 21, 2020 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) today announced that data from three studies of the UroLift® System were presented at the European Association of Urology (EAU) 2020 virtual congress, underscoring the safety and effectiveness of the minimally invasive treatment for benign prostatic hyperplasia (BPH) among broad patient groups.“The UroLift System is a standard of care treatment that provides rapid symptom relief and recovery for patients suffering from the burdensome symptoms of BPH,”1 said Dave Amerson, president of Teleflex Interventional Urology business unit. “Results from these studies are largely consistent with those found in previous...

Continue reading

Vita Mobile Systems Releases CEO Shareholder Letter on Acquisition Candidate and Audit Completion

IRVINE, CA, July 21, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Vita Mobile Systems, Inc. (OTC PINK: VMSI), a technology company specializing in big data via digital imaging on mobile devices, today released a letter to shareholders from CEO Sean Guerrero on a potential acquisition candidate and its current audit status. The letter is included in its entirety below:Dear Fellow Shareholders –It’s been an unprecedented year.  Like many other companies, we have had to learn to navigate the many challenges presented by the pandemic while continuing to push the company and our technology progressively forward.First, we apologize for the delay in providing an update on our audit.  We understand and echo the frustrations of our shareholders concerning the completion of the audit. Our auditor did not agree with the accounting of certain...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.